| ||||
| | | | |
AMI Research Updates Q4 Stock Report of NeoGenomics, Inc.
|
Key Largo, Fla., March 26, 2009 -- AMI Research, a division of Hawk Associates, today announced that it has updated its stock research coverage of NeoGenomics, Inc. (OTCBB: NGNM) based on the company’s Q4 '08 year end results. The complete 12-page report is available to download for free at the AMI Research website, http://www.amistockreports.com. NeoGenomics Inc. is a CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.org. About AMI Research AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst’s compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report. For more information, contact Frank Hawkins or Julie Marshall at 305-451-1888, email to: director@amistockreports.com or visit http://www.amistockreports.com. |
| ||||
